Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5
Chemical Name: Desmethylglycitein
whereas cytosolic fatty acid accumulates and glucose oxidation is elevated
Gynecol Oncol
44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17
Roscovitine (Seliciclib) D318088 Development and biological evaluation ofSeliciclib, also known as roscovitine and CYC202, is a n orally bioavailable, small molecule cyclin dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Seliciclib primarily inhibits CDK2 E, CDK2 A, CDK7 and CDK9 by competing for their ATP binding sites, leading to a disruption of cell cycle progression. In addition, this agent appears to interfere with CDK mediated phosphorylation of the carboxy terminal domain